DMD Celsis microsomes mean better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chien, J. Y.
Right arrow Articles by Slattery, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chien, J. Y.
Right arrow Articles by Slattery, J. T.

0090-9556/97/2510-1165-1175$02.00/0
DRUG METABOLISM AND DISPOSITION
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics
Vol. 25, No. 10


ARTICLE
Pharmacokinetic Consequences of Induction of CYP2E1 by Ligand Stabilization

Jenny Y. Chien, Kenneth E. Thummel, and John T. Slattery

Department of Pharmaceutics, University of Washington (J.T.S., J.Y.C., K.E.T.) and Fred Hutchinson Cancer Research Center (J.T.S.)

Models of the time course of the effect of P450 induction on substrate clearance have previously only considered induction through enhanced synthesis of protein. Induction of CYP2E1 does not always conform to this model, in that many chemicals induce the enzyme through stabilization of the protein apparently by binding to the active site. While such binding protects the enzyme from degradation, it also results in competitive inhibition of substrate clearance. We present a model based on experimental studies of chemical induction of CYP2E1 by ligand stabilization through which this mechanism of induction can be translated into its pharmacokinetic consequence with regard to clearance of substrate. CYP2E1 is considered to be localized in two pools: Pool 1 at which two mechanisms of degradation, fast and slow, operate and pool 2, at which only the slower mechanism operates. Binding of substrate to enzyme in pool 1 stabilizes it from degradation by the fast process, leaving only the slow process. Ligand stabilization therefore results in induction of CYP2E1 as enzyme accumulates as a consequence of unchanged synthesis. Binding of ligand to the active site results in competitive inhibition of the clearance of substrate. Model-based computer simulations show that the time course of interaction between inhibitor/inducer and substrate can be predicted from knowledge of I/Ki and S/Km and the synthesis and degradation kinetics of CYP2E1. The simulations demonstrate further that as long as inhibitor/inducer administration is not interrupted, the clearance of substrate will always be less than the value observed at low concentration of substrate even if the substrate concentration is raised to displace inhibitor/inducer from the active site. On the other hand, the degree of inhibition of clearance is less than would be seen if induction had not taken place. Clearance of substrate is observed to rise above the value observed in the absence of the inhibitor/inducer only after the inhibitor/inducer concentration declines low enough for substrate to gain access to the active site of the enzyme. The model-based simulations agree with reports of the interaction between isoniazid and acetaminophen in humans.


Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Toxicol SciHome page
J. S. Lee, W. O. Ward, D. C. Wolf, J. W. Allen, C. Mills, M. J. DeVito, and J. C. Corton
Coordinated Changes in Xenobiotic Metabolizing Enzyme Gene Expression in Aging Male Rats
Toxicol. Sci., November 1, 2008; 106(1): 263 - 283.
[Abstract] [Full Text] [PDF]


Home page
Hum Exp ToxicolHome page
C. E Schwab and H. Tuschl
In vitro studies on the toxicity of isoniazid in different cell lines
Human and Experimental Toxicology, November 1, 2003; 22(11): 607 - 615.
[Abstract] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Madan, R. A. Graham, K. M. Carroll, D. R. Mudra, L. A. Burton, L. A. Krueger, A. D. Downey, M. Czerwinski, J. Forster, M. D. Ribadeneira, et al.
Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes
Drug Metab. Dispos., April 1, 2003; 31(4): 421 - 431.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
P. Zhao and J. T. Slattery
Effects of Ethanol Dose and Ethanol Withdrawal on Rat Liver Mitochondrial Glutathione: Implication of Potentiated Acetaminophen Toxicity in Alcoholics
Drug Metab. Dispos., December 1, 2002; 30(12): 1413 - 1417.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
Z. Desta, N. V. Soukhova, and D. A. Flockhart
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A
Antimicrob. Agents Chemother., February 1, 2001; 45(2): 382 - 392.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
B. S. Mayhew, D. R. Jones, and S. D. Hall
An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation
Drug Metab. Dispos., September 1, 2000; 28(9): 1031 - 1037.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
M. G. Emery, C. Jubert, K. E. Thummel, and E. D. Kharasch
Duration of Cytochrome P-450 2E1 (CYP2E1) Inhibition and Estimation of Functional CYP2E1 Enzyme Half-Life after Single-Dose Disulfiram Administration in Humans
J. Pharmacol. Exp. Ther., October 1, 1999; 291(1): 213 - 219.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics.